Late failure of combined recombinant hepatitis B vaccine and lamivudine in treatment of a patient with chronic hepatitis B
SOUTHERN MEDICAL JOURNAL, cilt.97, sa.4, ss.407-409, 2004 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 97 Sayı: 4
- Basım Tarihi: 2004
- Doi Numarası: 10.1097/01.smj.0000091068.87861.ba
- Dergi Adı: SOUTHERN MEDICAL JOURNAL
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.407-409
- Anahtar Kelimeler: hepatitis B, lamivudine, recombinant vaccine, ANTI HBV VACCINE, IMMUNOTHERAPY, THERAPY, EFFICACY
- Ankara Üniversitesi Adresli: Hayır
Özet
We report the first case of a woman having chronic hepatitis B treated with a combination therapy of recombinant hepatitis B vaccine and lamivudine for 18 months. The main aims of such a combined therapy were to assess whether the concomitant anti-hepatitis B virus (HBV) vaccination might prevent the emergence of a mutant HBV and lead to sustained hepatitis B e antigen seroconversion with undetectable serum HBV DNA. The data from the present case demonstrated that combination of anti-HBV vaccine and lamivudine did not eliminate viral DNA despite prolonged treatment and did not have any effect on preventing resistant-type HBV. Although the combined therapy failed to reach the therapeutic endpoints, it concerned a single and unique patient. Hepatitis B vaccine and lamivudine for HBV treatment should be further investigated in randomized controlled trials.